Cargando…
Renal and Cardiovascular Effects of sodium–glucose cotransporter 2 (SGLT2) inhibition in combination with loop Diuretics in diabetic patients with Chronic Heart Failure (RECEDE-CHF): protocol for a randomised controlled double-blind cross-over trial
INTRODUCTION: Type 2 diabetes (T2D) and heart failure (HF) are a frequent combination, where treatment options remain limited. There has been increasing interest around the sodium–glucose cotransporter 2 (SGLT2) inhibitors and their use in patients with HF. Data on the effect of SGLT2 inhibitor use...
Autores principales: | Mordi, Natalie A, Mordi, Ify R, Singh, Jagdeep S, Baig, Fatima, Choy, Anna-Maria, McCrimmon, Rory J, Struthers, Allan D, Lang, Chim C |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5652490/ https://www.ncbi.nlm.nih.gov/pubmed/29042392 http://dx.doi.org/10.1136/bmjopen-2017-018097 |
Ejemplares similares
-
Renal and Cardiovascular Effects of SGLT2 Inhibition in Combination With Loop Diuretics in Patients With Type 2 Diabetes and Chronic Heart Failure: The RECEDE-CHF Trial
por: Mordi, Natalie A., et al.
Publicado: (2020) -
Research into the effect Of SGLT2 inhibition on left ventricular remodelling in patients with heart failure and diabetes mellitus (REFORM) trial rationale and design
por: Singh, Jagdeep S. S., et al.
Publicado: (2016) -
Microvascular disease and heart failure with reduced and preserved ejection fraction in type 2 diabetes
por: Mordi, Ify R., et al.
Publicado: (2020) -
Does dapagliflozin regress left ventricular hypertrophy in patients with type 2 diabetes? A prospective, double-blind, randomised, placebo-controlled study
por: Brown, Alexander J.M., et al.
Publicado: (2017) -
SGLT inhibitor adjunct therapy in type 1 diabetes
por: McCrimmon, Rory J., et al.
Publicado: (2018)